LGM
NMRA icon

Logos Global Management’s Neumora Therapeutics NMRA Stock Holding History

Logos Global Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$1.32M – 63
2024
Q3 		$1.32M Sell
100,000
-200,000
-67% -$2.33M 0.14% 52
2024
Q2 		$2.95M Sell
300,000
-82,345
-22% -$852K 0.24% 49
2024
Q1 		$6.19M Hold
382,345
– – 0.5% 43
2023
Q4 		$6.52M Buy
+382,345
New +$4.69M 0.61% 37

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Logos Global Management's NMRA Position: Q4 2024 in Review

Logos Global Management sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 100,000 shares — an estimated $1.32M sold.

Logos Global Management first reported a position in NMRA in Q4 2023 and held it in 4 quarters. The position peaked at $6.52M in Q4 2023. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Logos Global Management reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 100,000 Neumora Therapeutics shares in Q4 2024, an estimated $1.32M.
  • Logos Global Management first reported a position in Neumora Therapeutics in Q4 2023 and held it in 4 quarters.
  • Logos Global Management's Neumora Therapeutics position peaked at $6.52M in Q4 2023.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.